Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance

Edith A. Perez

Research output: Contribution to journalArticle

295 Citations (Scopus)

Abstract

Microtubules are important cellular targets for anticancer therapy because of their key role in mitosis. Microtubule inhibitors (MTI) such as taxanes, vinca alkaloids, and epothilones stabilize or destabilize microtubules, thereby suppressing microtubule dynamics required for proper mitotic function, effectively blocking cell cycle progression and resulting in apoptosis. In spite of their antitumor activity, innate or acquired drug resistance to MTIs such as the taxanes is common, limiting their overall clinical efficacy. Further insight into the mechanisms of action of microtubule-targeting drugs has lead to the discovery of novel agents that may provide higher efficacy with limited toxicity and help overcome resistance to conventional MTIs. This review will focus on the different mechanisms of action of MTIs, potential factors related to resistance and tolerability, and will discuss the recent approval as well as the development of new antineoplastic agents.

Original languageEnglish (US)
Pages (from-to)2086-2095
Number of pages10
JournalMolecular Cancer Therapeutics
Volume8
Issue number8
DOIs
StatePublished - Aug 1 2009

Fingerprint

Tubulin Modulators
Microtubules
Taxoids
Epothilones
Vinca Alkaloids
Drug Delivery Systems
Mitosis
Drug Resistance
Antineoplastic Agents
Action Potentials
Cell Cycle
Apoptosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Microtubule inhibitors : Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. / Perez, Edith A.

In: Molecular Cancer Therapeutics, Vol. 8, No. 8, 01.08.2009, p. 2086-2095.

Research output: Contribution to journalArticle

@article{54f4c26e0f7e44289a7c18064808276c,
title = "Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance",
abstract = "Microtubules are important cellular targets for anticancer therapy because of their key role in mitosis. Microtubule inhibitors (MTI) such as taxanes, vinca alkaloids, and epothilones stabilize or destabilize microtubules, thereby suppressing microtubule dynamics required for proper mitotic function, effectively blocking cell cycle progression and resulting in apoptosis. In spite of their antitumor activity, innate or acquired drug resistance to MTIs such as the taxanes is common, limiting their overall clinical efficacy. Further insight into the mechanisms of action of microtubule-targeting drugs has lead to the discovery of novel agents that may provide higher efficacy with limited toxicity and help overcome resistance to conventional MTIs. This review will focus on the different mechanisms of action of MTIs, potential factors related to resistance and tolerability, and will discuss the recent approval as well as the development of new antineoplastic agents.",
author = "Perez, {Edith A.}",
year = "2009",
month = "8",
day = "1",
doi = "10.1158/1535-7163.MCT-09-0366",
language = "English (US)",
volume = "8",
pages = "2086--2095",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Microtubule inhibitors

T2 - Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance

AU - Perez, Edith A.

PY - 2009/8/1

Y1 - 2009/8/1

N2 - Microtubules are important cellular targets for anticancer therapy because of their key role in mitosis. Microtubule inhibitors (MTI) such as taxanes, vinca alkaloids, and epothilones stabilize or destabilize microtubules, thereby suppressing microtubule dynamics required for proper mitotic function, effectively blocking cell cycle progression and resulting in apoptosis. In spite of their antitumor activity, innate or acquired drug resistance to MTIs such as the taxanes is common, limiting their overall clinical efficacy. Further insight into the mechanisms of action of microtubule-targeting drugs has lead to the discovery of novel agents that may provide higher efficacy with limited toxicity and help overcome resistance to conventional MTIs. This review will focus on the different mechanisms of action of MTIs, potential factors related to resistance and tolerability, and will discuss the recent approval as well as the development of new antineoplastic agents.

AB - Microtubules are important cellular targets for anticancer therapy because of their key role in mitosis. Microtubule inhibitors (MTI) such as taxanes, vinca alkaloids, and epothilones stabilize or destabilize microtubules, thereby suppressing microtubule dynamics required for proper mitotic function, effectively blocking cell cycle progression and resulting in apoptosis. In spite of their antitumor activity, innate or acquired drug resistance to MTIs such as the taxanes is common, limiting their overall clinical efficacy. Further insight into the mechanisms of action of microtubule-targeting drugs has lead to the discovery of novel agents that may provide higher efficacy with limited toxicity and help overcome resistance to conventional MTIs. This review will focus on the different mechanisms of action of MTIs, potential factors related to resistance and tolerability, and will discuss the recent approval as well as the development of new antineoplastic agents.

UR - http://www.scopus.com/inward/record.url?scp=68849087436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68849087436&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-09-0366

DO - 10.1158/1535-7163.MCT-09-0366

M3 - Article

C2 - 19671735

AN - SCOPUS:68849087436

VL - 8

SP - 2086

EP - 2095

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 8

ER -